A provider briefing on Citric Acid/Potassium Citrate availability in 2026, including prescribing implications, alternatives, and tools to help patients.
If your patients have been reporting difficulty filling prescriptions for Citric Acid/Potassium Citrate (Cytra-K, Polycitra-K, Virtrate-K), they're not imagining things. While this urinary alkalinizer is not in a formal FDA-declared shortage, real-world availability has been inconsistent across pharmacies and regions.
This briefing covers the current supply landscape, prescribing implications, therapeutic alternatives, cost considerations, and tools you can recommend to patients navigating availability challenges.
Citric Acid/Potassium Citrate oral solution has historically been produced by a limited number of generic manufacturers, including PAI Pharma, Chartwell RX, and Pharmaceutical Associates. The concentrated supplier base creates inherent vulnerability to supply disruptions.
Key contributing factors over the past few years:
The rising prevalence of nephrolithiasis in the U.S. (now affecting approximately 1 in 10 adults) has steadily increased demand for urinary alkalinizers, further straining an already thin supply pipeline.
The availability challenges with Citric Acid/Potassium Citrate have several practical implications for prescribers:
Citric Acid/Potassium Citrate is available primarily as an oral solution (334 mg citric acid/1,100 mg potassium citrate per 5 mL). The standard dosing is 5-15 mL diluted in water, four times daily after meals and at bedtime. A powder form (Poly-Citra K Crystals) also exists but may be even harder to locate.
When the oral solution is unavailable, Potassium Citrate extended-release tablets (generic Urocit-K, available in 5, 10, and 15 mEq strengths) represent the most straightforward therapeutic substitution for patients who can swallow tablets.
When switching between formulations, careful attention to milliequivalent (mEq) dosing is essential:
Ensure dose conversions are verified before switching to avoid under- or over-treatment.
Regardless of formulation, patients on potassium citrate therapy require periodic monitoring:
As of early 2026, the supply situation for Citric Acid/Potassium Citrate can be characterized as follows:
For uninsured or underinsured patients, cost can compound the access challenge:
The absence of a manufacturer savings program reflects the generic-only market status of this product. However, the relatively low cost with coupons makes it accessible for most patients.
Several tools can help streamline the process of getting patients their medication:
Medfinder offers a provider-facing tool that allows your staff to search for pharmacy availability by medication and location. This can be integrated into your workflow when patients report difficulty filling prescriptions. Rather than having patients call multiple pharmacies, direct them to medfinder.com/providers.
Direct patients to these resources:
When Citric Acid/Potassium Citrate oral solution is unavailable, consider these evidence-based alternatives:
The long-term outlook for Citric Acid/Potassium Citrate availability is cautiously optimistic. Multiple generic manufacturers remain in the market, and the medication is not facing patent or exclusivity barriers that would limit competition. However, the small market size and limited profit margins for generic liquid formulations mean that supply will likely remain somewhat fragile.
Providers who anticipate potential availability issues and have a contingency plan (alternative formulations identified, preferred pharmacies noted, patient education resources ready) will be best positioned to ensure continuity of care for their patients.
Citric Acid/Potassium Citrate availability challenges are a manageable clinical problem in 2026, not a crisis. The key is proactive planning: know your alternatives, familiarize yourself with tools like Medfinder for providers, and equip patients with the information they need to navigate the pharmacy landscape independently.
For your patients who need help finding this medication, direct them to medfinder.com/providers — and for a comprehensive patient-facing update, share our article on what patients need to know about Citric Acid/Potassium Citrate in 2026.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
